KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Operating Leases (2019 - 2025)

Travere Therapeutics (TVTX) has disclosed Operating Leases for 7 consecutive years, with $17.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 1.06% year-over-year to $17.0 million, compared with a TTM value of $17.0 million through Dec 2025, down 1.06%, and an annual FY2025 reading of $17.0 million, down 1.06% over the prior year.
  • Operating Leases was $17.0 million for Q4 2025 at Travere Therapeutics, up from $12.6 million in the prior quarter.
  • Across five years, Operating Leases topped out at $33.5 million in Q2 2022 and bottomed at $12.6 million in Q3 2025.
  • Average Operating Leases over 5 years is $24.5 million, with a median of $25.1 million recorded in 2024.
  • The sharpest move saw Operating Leases rose 1.42% in 2023, then tumbled 47.04% in 2025.
  • Year by year, Operating Leases stood at $31.5 million in 2021, then fell by 12.66% to $27.5 million in 2022, then dropped by 17.8% to $22.6 million in 2023, then decreased by 23.97% to $17.2 million in 2024, then dropped by 1.06% to $17.0 million in 2025.
  • Business Quant data shows Operating Leases for TVTX at $17.0 million in Q4 2025, $12.6 million in Q3 2025, and $19.7 million in Q2 2025.